Acquired paclitaxel-resistant MDA-MB-231 cancer cells response to bexarotene treatment
Summary:
Analysis of acquired paclitaxel (PTX)-resistant MDA-MB-231 cells treated with bexarotene-PTX or PTX. Retinoid X receptor-selective agonist bexarotene was efficacious in treating chemo-resistant cancer cells. Results provide insight into bexarotene’s role in overcoming acquired drug resistance.
GPL96:
[HG-U133A] Affymetrix Human Genome U133A Array
Citation:
Luo W, Schork NJ, Marschke KB, Ng SC et al. Identification of polymorphisms associated with hypertriglyceridemia and prolonged survival induced by bexarotene in treating non-small cell lung cancer. Anticancer Res 2011 Jun;31(6):2303-11. PMID: 21737656
